Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel
HONG KONG, Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to hold a results presentation for the first time in six years....
Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
Highlights: Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; Operational quality of core industries steadily improved, with industrial...
Fosun Pharma Announces 2026 Interim Results
Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026...
Fosun International Issues Positive Profit Alert: Profit Attributable to Owners of the Parent for 1H2026 Expected to be Approx. RMB 1.5 Billion to RMB1.8 Billion
HONG KONG, July 29, 2026 /PRNewswire/ -- On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion...
Sisram Medical's China Manufacturing Facility Commences Operations as First Locally Produced Alma Rejuve Rolls Off the Line
Localization strategy advances with strengthened end-to-end capabilities across R&D, manufacturing and commercialization HONG KONG, June 29, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group...
Sisram Medical Investor Day Key Takeaways
Advancing Global Medical Aesthetics Strategy and Unl ock ing Wellness Platform Value HONG KONG, May 27, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"),...
Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
HONG KONG, May 27, 2026 /PRNewswire/ -- On 27 May 2026, Fortune China magazine released its 2026 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was...
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total...
Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles
HONG KONG, April 1, 2026 /PRNewswire/ -- On 31 March, Fosun International held its 2025 annual results presentation in Shanghai. Guo Guangchang, Chairman of Fosun International; Wang Qunbin, Co-Chairman of Fosun International; Chen Qiyu, Co-CEO of...
Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas
HONG KONG, March 31, 2026 /PRNewswire/ -- On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International's 2025 annual results presentation that the RMB23.4 billion impairment provision was a "prudent...